The California Institute for Regenerative Medicine (CIRM) applauds and acknowledges the historic significance of the Food and Drug Administration (FDA) approval of Vertex and CRISPR Therapeutics’ CRISPR-based gene therapy (Casgevy) for sickle cell disease. As the first regulatory authorization of a CRISPR-based gene editing therapy in the world, this brings forth a new era of treatment options … Continue reading Statement from CIRM on the FDA Approval of Gene Therapies for Sickle Cell Disease
CIRM invests $17.5 million in clinical-stage research that includes spina bifida trial
Diana Farmer, MD and Aijun Wang, PhD. Photo courtesy UC Davis Health The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, has awarded $17.5 million to fund clinical-stage research projects aimed at advancing stem cell and gene therapies for a variety of conditions, ranging from neurodegenerative diseases to blood … Continue reading CIRM invests $17.5 million in clinical-stage research that includes spina bifida trial
CIRM Joins World AIDS Day Campaign, Commits $104 Million for HIV Research
John A. Zaia, MD, of Beckman Research Institute of City of Hope This year marks the 35th commemoration of World AIDS Day, a global event that aims to end human immunodeficiency virus (HIV) related stigma, honor people lost to the disease, and reaffirm the commitment to ensuring HIV is no longer a public health threat. … Continue reading CIRM Joins World AIDS Day Campaign, Commits $104 Million for HIV Research
Empowering Diversity, Equity, and Inclusion: A Week at the SACNAS National Diversity in STEM Conference
When I joined the California Institute for Regenerative Medicine (CIRM) as the new Community Outreach Manager, I was drawn to the Agency’s dedication to diversity, equity, and inclusion (DEI). Some DEI achievements include: Requiring plans for inclusion of diverse or underserved demographic groups in CIRM-funded clinical trials Providing valuable educational opportunities in regenerative medicine for … Continue reading Empowering Diversity, Equity, and Inclusion: A Week at the SACNAS National Diversity in STEM Conference
Upcoming Funding Opportunity: ReMIND-L Awards
The California Institute for Regenerative Medicine (CIRM) is pleased to announce ReMIND-L, the first funding opportunity under CIRM’s ReMIND Program – a new discovery stage initiative supporting foundational research in the study of neuropsychiatric diseases. Applications are due March 5, 2024 by 2:00 p.m. PST. Applications will be available mid-December 2023 but no later than two months … Continue reading Upcoming Funding Opportunity: ReMIND-L Awards
CIRM invests more than $42 million in translational research
The California Institute for Regenerative Medicine awarded $42.1 million for translational research projects. These projects target brain cancers, salivary gland conditions, and a rare metabolic disease. CIRM’s Translational program supports promising stem cell and gene projects. It helps teams complete key activities needed for clinical studies or broad use. These activities can involve therapeutic candidates, … Continue reading CIRM invests more than $42 million in translational research
CIRM-Funded Program For Rare Pediatric Disease
The California Institute for Regenerative Medicine (CIRM) congratulates Rocket Pharmaceuticals, Inc., a leading late‑stage biotechnology company. The company recently received U.S. FDA acceptance of the Biologics License Application (BLA) and Priority Review for RP-L201 (marnetegragene autotemcel). CIRM helped support development of this lentiviral‑vector gene therapy for severe Leukocyte Adhesion Deficiency‑I (LAD‑I). What the BLA Means … Continue reading CIRM-Funded Program For Rare Pediatric Disease
CIRM brings together experts in the 6th annual Alpha Clinics Network Symposium at UC Irvine
CIRM’s Alpha Clinics network specializes in delivering stem and gene therapy trials. Its success relies on strong partnerships with patients, clinicians, and trial sponsors. The network includes nine leading medical centers across California. Each year, CIRM hosts a public Alpha Clinic Symposium to explore key issues in stem and gene therapies. UC Irvine hosted the … Continue reading CIRM brings together experts in the 6th annual Alpha Clinics Network Symposium at UC Irvine
CIRM approves new plan to invest $110 million for neuropsychiatric disease research
The California Institute for Regenerative Medicine (CIRM) approved a new program called ReMIND at its September ICOC meeting. The program will award up to $110 million to advance basic research in neuropsychiatric diseases—one of California’s largest investments in this area. ReMIND (Research using Multidisciplinary, Innovative Approaches in Neuro Diseases) aims to accelerate discoveries that improve … Continue reading CIRM approves new plan to invest $110 million for neuropsychiatric disease research
CIRM invests nearly $44 million to advance regenerative medicine research and manufacturing in California
Novoglia, Inc. was awarded a $1.4 million award to support the development of a cell therapy for the treatment of ALSP. Pictured are Novoglia, Inc. co-founders Sunil Gandhi, PhD, Robert Spitale, PhD, and Mathew Blurton-Jones, PhD. September 29, 2023 South San Francisco, CA – The California Institute for Regenerative Medicine (CIRM), the world’s largest institution … Continue reading CIRM invests nearly $44 million to advance regenerative medicine research and manufacturing in California